Roche's divarasib cuts death risk 44% in a head-to-head against Amgen's and BMS's KRAS G12C drugs
- At ESMO 2026 Roche detailed Krascendo 1, a Phase 3 comparing its next-generation KRAS G12C inhibitor divarasib with sotorasib or adagrasib in previously treated KRAS G12C-mutant non-small cell lung cancer.
- Divarasib reduced the risk of death by 44% versus the two marketed drugs, per Endpoints News.
- Earlier toplines had reported a progression-free survival win and no new safety signals.
💡 Points
A direct, randomized survival win over both approved G12C drugs is rare in oncology, where new agents usually rely on cross-trial comparisons. It gives Roche a strong claim on the second-line standard and puts pressure on Amgen and Bristol Myers Squibb, though the contest is moving to first line, where Revolution Medicines' RAS programs set the bar.
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor's win over rivals in lung cancer trial ↗